1.
Baseline characteristics of enrolled gastric cancer patients (N=100)
| Variable | Overall [n (%)] | Neoadjuvant group [n (%)] | Adjuvant group [n (%)] | P | |||
| SOX (N=25) | CapeOX (N=25) | SOX (N=25) | CapeOX (N=25) | ||||
| BMI, body mass index; SOX, oxaliplatin plus S-1; CapeOX, oxaliplatin plus capecitabine; Fisher’s exact test was used as an alternative to Chi-square test when the number in one of the cells is smaller than 5. | |||||||
| Age (year) | 0.201 | ||||||
| <65 | 69 (69) | 13 (52) | 19 (76) | 19 (76) | 18 (72) | ||
| ≥65 | 31 (31) | 12 (48) | 6 (24) | 6 (24) | 7 (28) | ||
| Gender | 0.123 | ||||||
| Male | 76 (76) | 19 (76) | 17 (68) | 17 (68) | 23 (92) | ||
| Female | 24 (24) | 6 (24) | 8 (32) | 8 (32) | 2 (8) | ||
BMI (kg/m2) (
)
|
23.2±3.3 | 23.4±3.1 | 22.4±3.4 | 23.8±3.7 | 23.1±3.0 | 0.567 | |
| Clinical T | 0.718 | ||||||
| T2 | 10 (10) | 1 (4) | 4 (16) | 3 (12) | 2 (8) | ||
| T3 | 31 (31) | 8 (32) | 5 (20) | 9 (36) | 9 (36) | ||
| T4a | 58 (58) | 16 (64) | 15 (60) | 13 (52) | 14 (56) | ||
| T4b | 1 (1) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | ||
| Clinical N | 0.839 | ||||||
| N0 | 34 (34) | 10 (40) | 7 (28) | 7 (28) | 10 (40) | ||
| N1 | 28 (28) | 5 (20) | 8 (32) | 8 (32) | 7 (28) | ||
| N2 | 30 (30) | 6 (24) | 8 (32) | 9 (36) | 7 (28) | ||
| N3 | 8 (8) | 4 (16) | 2 (8) | 1 (4) | 1 (4) | ||
| Histological type | 0.460 | ||||||
| Differentiated | 27 (27) | 5 (20) | 8 (32) | 9 (36) | 5 (20) | ||
| Undifferentiated | 73 (73) | 20 (80) | 17 (68) | 16 (64) | 20 (80) | ||
| Lauren type | 0.194 | ||||||
| Intestinal | 36 (36) | 12 (48) | 11 (44) | 7 (28) | 6 (24) | ||
| Diffuse | 46 (46) | 11 (44) | 12 (48) | 12 (48) | 11 (44) | ||
| Mixed | 18 (18) | 2 (8) | 2 (8) | 6 (24) | 8 (32) | ||
| Comorbid illness | 0.313 | ||||||
| One or more | 37 (37) | 12 (48) | 7 (28) | 7 (28) | 11 (44) | ||
| None | 63 (63) | 13 (52) | 18 (72) | 18 (72) | 14 (56) | ||